William Blair Has Positive Estimate for TLX FY2025 Earnings

Telix Pharmaceuticals Limited (NASDAQ:TLX) – Equities research analysts at William Blair increased their FY2025 earnings estimates for Telix Pharmaceuticals in a research report issued to clients and investors on Tuesday, October 14th. William Blair analyst A. Hsieh now expects that the company will earn $0.09 per share for the year, up from their prior forecast of $0.06. William Blair has a “Outperform” rating on the stock. The consensus estimate for Telix Pharmaceuticals’ current full-year earnings is $0.24 per share. William Blair also issued estimates for Telix Pharmaceuticals’ FY2026 earnings at $0.20 EPS.

Several other equities research analysts have also recently weighed in on TLX. Wedbush reiterated an “outperform” rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a research note on Thursday, August 28th. HC Wainwright reduced their target price on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, September 10th. Citigroup started coverage on shares of Telix Pharmaceuticals in a research note on Thursday, September 18th. They issued a “buy” rating and a $22.00 target price for the company. Canaccord Genuity Group upgraded shares of Telix Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 6th. Finally, UBS Group reduced their target price on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Telix Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Telix Pharmaceuticals Stock Performance

TLX stock opened at $10.86 on Thursday. Telix Pharmaceuticals has a 52-week low of $8.93 and a 52-week high of $30.36. The company has a 50-day moving average of $10.31 and a two-hundred day moving average of $14.16.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in TLX. Private Advisor Group LLC acquired a new position in Telix Pharmaceuticals in the first quarter worth about $170,000. ABC Arbitrage SA acquired a new position in Telix Pharmaceuticals in the first quarter worth about $451,000. Blair William & Co. IL acquired a new position in Telix Pharmaceuticals in the second quarter worth about $217,000. Vanguard Personalized Indexing Management LLC acquired a new position in Telix Pharmaceuticals in the second quarter worth about $297,000. Finally, Pier Capital LLC acquired a new position in Telix Pharmaceuticals in the second quarter worth about $3,037,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.